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Abstract
Whole genome DNA sequencing was used to decrypt the phylogeny of multiple samples from 
distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. 
Mutations were present at high levels in morphologically normal tissue distant from the cancer 
reflecting clonal expansions, and the underlying mutational processes at work in morphologically 
normal tissue were also at work in cancer. Our observations demonstrate the existence of on-going 
abnormal mutational processes, consistent with field-effects, underlying carcinogenesis. This 
mechanism gives rise to extensive branching evolution and cancer clone mixing as exemplified by 
the coexistence of multiple cancer lineages harboring distinct ERG fusions within a single cancer 
nodule. Subsets of mutations were shared either by morphologically normal and malignant tissue 
or between different ERG-lineages, indicating earlier or separate clonal cell expansions. Our 
observations inform on the origin of multifocal disease and have implications for prostate cancer 
therapy in individual cases.
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Prostate cancer is commonly multifocal1, although the origin of multifocal disease remains 
controversial. Analyses of patterns of allele loss have suggested the independence of most 
individual foci2,3. However such studies cannot exclude the presence of common underlying 
mutations not detected by the methods employed. Recent attempts to unravel the origins of 
multifocal disease using high-resolution genome technologies have also led to conflicting 
data with different authors concluding either that all foci in a single prostate are related4 or 
that all foci are unrelated5. To gain further insights into the mechanism of prostate cancer 
development particularly the origin of multifocal disease we selected three representative 
prostate cancers (Fig.1, Supplementary Fig.1) that had been ERG-status mapped using the 
FISH break-apart method6,7. Twelve cancer samples and three samples designated as 
morphologically normal prostate based on central pathology review, were analyzed using 
paired-end massively-parallel DNA sequencing of complete genomes to generate 
comprehensive catalogues of genetic alterations (for coverage statistics see Supplementary 
Table 1). For 3D representations of each prostate and clinical characteristics see respectively 
Supplementary Fig. 2 and Supplementary Table 2. Prostates were named according to their 
Cancer Research UK project designation: Cases 6, 7 and 8.
Somatic mutations, absent from cancer and blood samples, were observed at significant 
levels in morphologically normal prostate tissue distant from cancer in Case 6 (518 
substitutions) and in Case 7 (454 substitutions) (Supplementary Fig. 3), some of which may 
have potential functional significance (Table 1). The presence of substitution mutations in 
morphologically normal prostate tissue was confirmed in validation DNA-sequencing 
experiments to an average read depth of 10,000. Substitutions were present in an estimated 
~48%, and ~42% of cells in morphologically normal samples from Case 6 and Case 7 
respectively (Supplementary Fig. 3b)), demonstrating clonal expansions of cells within 
morphologically normal prostate tissue, in agreement with studies using mitochondrially-
encoded enzyme cytochrome c oxidase as a marker8.
Aiming to understand the tumor subclonal architecture and their phylogeny, we initially 
constructed phylogenetic trees based on copy number (Supplementary Fig. 4 & 5, 
Supplementary Data Set 1) and substitution data. We adapted our previously developed 
Bayesian Dirichlet process to identify clusters of substitutions in n dimensions9, where n is 
the number of samples from the case, such that shared and unique subclones could be 
identified between related samples (Fig. 2d and Supplementary Fig. 6). To further explore 
the fine details and verify the main features of the phylogeny tree and clonal structure, a 
selection of substitutions from each potential relationship between samples were sequenced 
to an average read depth of 10,000 in independent DNA sequencing analyses, verifying 279 
mutations across all samples. This provided us with our final integrated phylogenetic trees 
(Fig. 2a-c) and final list of somatic point mutations (Supplementary Data Set 2). The 
structure of these trees was also supported by verified insertions, deletions and breakpoints 
(Supplementary Data Set 3 & 4). The single cancer mass from Patient 6 contained three 
independent cancer clones represented by samples 6_T2, 6_T3 and 6_T4 (Fig. 2a), with a 
single verified substitution linking 6_T1/6_T2 and 6_T3. Patient 7 contained at least three 
independent cancer lineages: one (7_T3) representing the smaller cancer nodule and two 
(7_T1/7_T2 and 7_T4/7_T5) present in the larger cancer mass (Fig. 2b). Ten mutations were 
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common to the morphologically normal prostate sample and to cancer samples 7_T1 and 
7_T2, and three mutations joined 7_T4/7_T5 to the separate multifocal lesion 7_T3. These 
observations show that Prostate 7 contains at least two clones of cells that existed prior to 
the formation of the distinct cancers lineages. Prostate 8 contained two cancer lineages 
represented by 8_T1/8_T2 and 8_T3 (Fig. 2c), with 43 substitutions shared between all three 
tumor samples, 8_T1, 8_T2 and 8_T3, 8 of which were also present in distant 
morphologically normal sample 8_N.
Complex patterns of ERG alteration were observed in samples from Patient 6 and Patient 7 
(Fig. 3); each main lineage contained at least one and in some cases two unique TMPRSS2-
ERG fusions with distinct breakpoint locations within the TMPRSS2 and ERG genes (Fig. 2, 
Table2). The presence of multiple distinct TMPRSS2-ERG fusions was demonstrated by 
direct PCR across the breakpoint and by an ERG FISH break-apart assay (Table 2, Fig. 1b,c, 
Supplementary Fig. 1). In this respect TMPRSS-ERG fusions could be considered to be 
similar to the convergent gene alterations observed in kidney cancer where distinct 
alterations of genes such as SETD2, PTEN, and KDM5C were observed in different parts of 
the same cancer10. A deletion on Chromosome 8 exhibited a very similar pattern of 
alterations (Supplementary Fig. 7), but we did not see convergent evolution for other 
potential driver genes (Supplementary Table 3). Where two TMPRSS2-ERG fusions existed 
in a single lineage we were unable to determine whether these fusions co-existed at any time 
in the same cell as reported previously11 and as implied by the phylogenic tree. However the 
FISH assay (Fig 1b,c) demonstrated that in sample 7_T4 the two TMPRSS2_ERG fusions 
were present in distinct cell populations at the time that the cancer sample was taken. 
Moreover, an additional separate ERG breakpoint was detected in a region of the cancer that 
had not been sampled in the DNA sequencing studies (TERG J). The occurrence of several 
TMPRSS2-ERG fusions is a single cancer mass is consistent with previous FISH-based 
studies reporting multiple ETS fusions in a low proportion of individual cancer foci11. ERG 
alterations are believed to represent a relatively early event in cancer development in 
agreement with their occurrence in prostatic intraepithelial neoplasia (PIN)6, but our 
observations suggest that they may not always be present at the very first cellular expansion. 
Mutations shared either between different ERG-lineages or between cancer and 
morphologically normal tissue may represent earlier clonal cell expansions on the same 
lineage (Fig. 2a-c). Alternatively they could represent separate clones of cells within which 
multiple independent cancer lineages developed.
Recently, we identified 21 distinct mutational signatures from 7,042 samples across 30 
different cancer types12. The contribution of mutational processes was calculated for 
prostate cancer as previously described12,13 (Fig. 4). A signature (designated Signature 1A 
in Ref. 12) associated with spontaneous deamination of 5-methyl-cytosine at CpG sequences 
explained ~50% of all of our mutations. Two additional signatures with unknown etiology, 
designated Signature 5 and Signature 8, best explained the remaining somatic mutations. 
Signature 5, present in all prostate samples may reflect an endogenous mutational process12. 
Signature 8, present in two cancer samples from a single cancer nodule, is characterized by 
weak C>A strand bias. Critically these observations show that the same mutational 
processes, giving rise to Signatures 1a and 5, are detected both in cancer and in matched 
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morphologically normal prostate tissue. We identified clustering of C>T and C>G mutations 
previously referred to as kataegis14 and complex interdependent translocations and deletions 
called chromoplexy15 in some cancer lineages (Supplementary Fig. 8 & 9).
Next generation sequence technologies have previously been used to identify critical genetic 
processes in prostate cancer development15-19. Our results demonstrate the presence of 
clonal expansions or fields of cells in the morphologically normal prostate that provide a 
background against which prostate cancer develops. A recent study on a 115 year old 
woman identified 424 point mutations, thought to result from somatic mosaicism, in the 
rapidly dividing tissue blood, but failed to detect any mutations in brain tissue20. The 
presence of mutations in blood was accompanied by telomere attrition that was not observed 
in other tissues. Prostate is considered to be a relatively quiescent tissue21, and we found 
that the telomeres in morphologically normal tissue from Cases 6 and 7 had not undergone 
attrition, being of comparable length to telomeres in adjacent cancer. The processes at work 
in morphologically normal prostate therefore appear to be distinct from those reported for 
blood (see Supplementary Notes for full discussion). Whether the clones of cells observed in 
morphologically normal prostate are generated by a pathological process or are the product 
of somatic mosaicism involving unexpectedly high mutation rates, the resulting clonal fields 
of cells may influence cancer development and/or contribute to multifocality and the 
presence of multiple cancer lineages in a single cancer mass. Evidence for a field effect in 
prostate cancer is also supported by studies demonstrating tumor-like alterations in 
cytomorphology, gene expression, epigenetics in adjacent morphologically normal tissue, 
and the presence of multifocal disease in a high proportion of prostates. Field effects have 
also been proposed for oral cancer22, head and neck cancer23 and breast cancer24. Our 
results have implications for the use of cancer focal therapy when targeting a single nodule 
of cancer within the prostate25,26 and for potential chemotherapeutic approaches. We 
propose that (i) focal therapy may only be curative if surrounding clonal cell populations 
within morphologically normal tissue were also ablated, and (ii) cancer heterogeneity may 
hinder therapeutic targeting and biomarker investigation.
ONLINE METHODS
Sample Selection and Fluorescence in situ Hybridisation
Samples for analysis were collected from prostatectomy patients at the Addenbrooke’s 
Hospital (see Supplementary Table 2). The study was approved by the Trent Multicentre 
Research Ethics Committee. Informed consent was obtained for all patients. Prostates were 
sliced and processed as described previously31. In brief, a single 5 mm slice of the prostate 
was selected for research purposes. 4 or 6 mm cores were taken from the slice and frozen. 
Frozen cores were mounted vertically and sectioned transversely giving a single 5 μm frozen 
section for H&E staining followed by 6×50 μm sections for DNA preparation. The presence 
of or complete absence of cancer was confirmed independently by three pathologists in 
central pathology review of the 5 μm H&E stained tissue slice immediately adjacent to 
tissue slices used for DNA preparation. The ERG fluorescence in situ hybridisation break-
apart assay for assessing ERG gene rearrangement was performed as described previously6, 
both (i) on whole-mount formalin-fixed sections, taken immediately adjacent to the research 
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slice, and (ii) on the frozen slices, immediately adjacent to the samples selected for DNA 
sequencing that had been initially subject to H&E staining. In all cases, the ERG status 
determined by these two methods and shown in Figure 1, were consistent.
DNA sequencing
Samples and Massively Parallel Sequencing—DNA was extracted from 18 samples 
from 3 patients: 12 prostate cancer samples, 3 adjacent morphologically normal prostate 
samples and 3 matched bloods. Paired-end whole genome sequencing of the samples was 
performed at Illumina, Inc. Paired-end libraries were manually generated from 1 μg of 
gDNA using the Illumina Paired End Sample Prep Kit (Catalog # PE-102-1002). 
Fragmentation was performed with Covaris E220. After end repair, A-tailing, and adapter 
ligation as per the sample prep kit instructions, libraries were manually size-selected using 
agarose gel electrophoresis, targeting 300 bp inserts. Adapter-ligated libraries were PCR 
amplified for 10 cycles and purified through a second agarose gel electrophoresis. Final 
libraries were QC’ed on a Agilent Bioanalyzer and quantified by qPCR and/or picogreen 
fluorimetry. Samples were clustered with Illumina v1.5 flowcells using the Illumina cBot 
with the TruSeq Paired End Cluster Kit v3. Flowcells were sequenced as 100 base paired-
end (non-indexed) reads on the Illumina HiSeq2000 using TruSeq SBS chemistry v3 to a 
target depth of 50× for the tumour samples and 30× for adjacent morphologically normal 
and blood samples. The Burrows-Wheeler Aligner (BWA) was used to align the sequencing 
data from each lane to the GRCh37 reference human genome32. Lanes that pass quality 
control are merged into a single well-annotated sample BAM file with duplicate reads 
removed. This data has been submitted to the European Genome-Phenome Archive 
(EGAD00001000689).
Mutation-Calling: Substitutions—CaVEMan (Cancer Variants Through Expectation 
Maximization), an in-house bespoke algorithm developed at the Sanger Institute, was used 
for calling somatic substitutions. CaVEMan utilises a Bayesian expectation maximization 
(EM) algorithm: Given the reference base, copy number status and fraction of aberrant 
tumor cells present in each cancer sample, CaVEMan generates a probability score for 
potential genotypes at each genomic position. A ‘somatic’ probability of 95% and above 
was applied as a cut off. Further post-processing filters were applied to eliminate false 
positive calls arising from genomic features that generate mapping errors and systematic 
sequencing artifacts. In addition to the standard filters applied in the Sanger pipeline we 
designed project-specific filters to improve the positive predictive value of our callers based 
on results from visually inspecting and calling many hundreds of variants. Visually 
inspecting involves checking that the variant was in at least three reads, not in any reads of 
control, no strand bias, no correlation of the reads containing the variant and read quality, 
not in a location where indels are also detected, not in a poorly mapped region, and not in a 
repeat region. Substitutions that are found in the WGS data of more than 2.5% of a batch of 
465 normal non-malignant samples from a range of tissue types were also removed. 
Additional visual verification across all samples for a patient was performed for all non-
intronic gene substitutions, all substitutions in adjacent morphologically normal samples, 
potential “field effect” substitutions, substitutions shared between adjacent morphologically 
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normal and neoplastic samples, and the rare predicted substitutions apparently violating the 
inferred phylogeny.
Mutation-Calling: Insertions/Deletions—Insertions and deletions in the tumor, 
morphologically normal and matched blood control genomes were called using a modified 
Pindel version 0.2.0 on the NCBI37 genome build33. As with the substitutions, all standard 
Sanger pipeline filters were applied, as well as a custom filter built based on results from 
visually calling identified variants. Indels that were detected by Pindel in more than two 
samples from a series of hundreds of malignant non-prostate tissue were also removed. If an 
indel detected by Pindel that does not pass the filters is found in another sample for that 
patient and does pass all filters, it is also included. From those indels that passed all filters, 
for each sample, up to one hundred variants were validated by capillary sequencing. In 
addition, visual verification across all samples for a patient was performed for all indels 
occurring within genes, all indels in adjacent morphologically normal samples, potential 
“field effect” indels, those indels that were not supported by the phylogeny and a sampling 
of variants from each phylogeny relationship.
Mutation-Calling: Structural Variants—Brass (Breakpoints via assembly), an in-house 
bespoke algorithm developed at the Sanger Institute, was used for detecting structural 
variants. In Brass phase 1, discordant read pairs are detected and integrated to find regions 
of interest. These regions of interest are removed if they have been found in the matched 
blood normal sample, have been detected as germline in PCR validation of any other 
sample, have a low numbers of reads supporting them or appear to be in a “difficult” region 
of the genome. For a subset of regions, validation was performed by gel electrophoresis 
PCR using custom-designed PCR primers across the rearrangement breakpoint as previously 
described34 and for those products that give a band the precise location and nature of the 
breakpoint was determined by standard Sanger capillary sequencing methods. In the cases 
where the PCR experiments failed, Brass phase 2 was applied to the remaining predicted 
somatic structural variants. This gathers reads around the region, including half-unmapped 
reads and performs a local de novo assembly using Velvet35. Identifiable breakpoints have a 
distinctive De Bruijn graph pattern and allowed the breakpoint to be regenerated down to 
base pair resolution. Any breakpoints where an exact location could not be determined were 
removed. To ensure that breakpoints shared between samples in a patient were picked up, 
in-silico and PCR cross-sample experiments were performed. All breakpoints reported have 
been visually verified to ensure the presence of discordant reads and checked to ensure they 
were not in repeat regions.
To detect rearrangements involved in chromoplexy, a recently described process generating 
chained rearrangements we applied ChainFinder15. We used default parameters, selecting 
the rearrangements from 57 prostate genomes as background. As input copy number data, 
we used data derived from Affymetrix SNP 6.0 arrays, and processed using ASCAT36. As 
input structural variants, for each patient, we combined all high confidence breakpoints 
detected in all samples of that patient. One chained event was manually filtered, as it 
combined somatic rearrangements present in separate subpopulations in different samples, 
and hence could not have occurred as one chromoplexy event.
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Mutation-Calling: Copy Number—The Battenberg algorithm was used to detect clonal 
and sub-clonal somatic copy number alterations (CNA) and estimate ploidy and tumour 
content from the NGS data as previously described9. Briefly, germline heterozygous SNPs 
are phased using Impute2 and a- and b- alleles assigned. Data is segmented using piecewise 
constant fitting37 and subclonal copy number segments are identified as those with 
deviations in the b-allele frequencies from the values expected when all cells have a 
common copy number in that segment, using a t-test. Ploidy and tumour content are 
estimated using the same method used by ASCAT36.
Construction of phylogenetic trees
For each patient, phylogenetic trees were constructed separately using (i) copy number 
aberrations (CNAs) and (ii) point mutations. Clonal and subclonal CNAs were identified 
using the previously described Battenberg algorithm9. This method achieves high sensitivity 
for the detection of CNAs found in small proportions of cells by phasing heterozygous SNPs 
into parent specific haplotype blocks. Joint analysis of SNPs within these blocks, rather than 
single SNPs, allows the resolution of CNAs found in ~5% of cells, with 30× sequencing 
depth. Matching of copy number and rearrangement breakpoints, supported by visual 
inspection of allele frequency and logR plots, was used to identify CNAs common to 
multiple samples. Point mutations were analysed using an adaptation of a previously 
described Bayesian Dirichlet process. Mutations within each sample are modelled as 
deriving from an unknown number of subclones, each of which is present at an unknown 
fraction of tumour cells and contributes an unknown proportion of all somatic mutations, 
with all the unknown parameters jointly estimated. In order to identify clusters of mutations 
that are common to 2 or more samples, the Dirichlet process was extended into 2 
dimensions, with the fraction of tumour cells bearing a mutation in each of a pair of samples 
jointly estimated from the number of reads observed in each sample. The presence of 
clusters of unique or shared mutations can be inferred from the position of the peaks in the 
resulting 2-dimensional probability density.
Dirichlet process clustering
We used a previously developed Bayesian Dirichlet process to model clusters of clonal and 
subclonal point mutations, allowing inference of the number of subclones, the fraction of 
cells within each subclone and the number of mutations within each clone36. Within this 
model, the number of reads bearing the ith mutation, yi, is drawn from a binomial 
distribution
where Ni is the total number of reads at the mutated base and ζi is the expected fraction of 
reads that would report a mutation present in 100% of tumour cells at that locus. πi ∈ (0, 1), 
the fraction of tumour cells carrying the ith mutation, is modelled as coming from a 
Dirichlet process. We use the stick-breaking representation of the Dirichlet process:
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where ωh is the weight of the hth mutation cluster, i.e. the proportion of all somatic 
mutations specific to that cluster. This model was extended into n dimensions, where n is the 
number of related samples, with the number of mutant reads obtained from each sample 
modelled as an independent binomial distribution, each with an independent π drawn with a 
Dirichlet process from a base distribution U(0,1). Gibbs sampling was used to estimate the 
posterior distribution of the parameters of interest, implemented in R, version 2.11.1. The 
Markov chain was run for 500 iterations, of which the first 100 were discarded. In order to 
plot the mutation density, each possible pair of related samples was treated separately. The 
median of the density was estimated from πh, each weighted by the associated value of ωh, 
using a bivariate Gaussian kernel, implemented in the R library KernSmooth. Median values 
were then plotted using the R function ‘levelplot’, using a colour palette graduated from 
white (low probability of a mutation) to red (high probability of a mutation).
Targeted PCR and MiSeq sequencing of selected mutations and structural variants
PCR primers for somatic substitutions and indels were designed using Primer-Z38, with 
known SNPs and human repeats masked. All amplicons were designed to be a maximum of 
500 bp and all variants of interest were checked to be within a read generated on a 2×250bp 
MiSeq run. DNA was amplified using Phusion HotStart II DNA polymerase kit (Thermo 
Fisher Scientific) and thermo cycler. DNA was denatured at 98 °C for 30 seconds followed 
by 30 cycles of denaturing at 98 °C for 10 seconds, annealing at 65 °C for 20 seconds and 
extension at 72 °C for 20 seconds. Products were incubated at 72 °C for 5 minutes before 
cooling to 4 °C. All PCR products were analysed using 96 well 2% agarose E-gel with 
ethidium bromide (Life Technologies). If no detectable band was present these reactions 
were repeated using an annealing temperature of 60 °C. 2 μl of PCR mixture for each sample 
of DNA were pooled. Pooled DNA was diluted 1:10, and tagged with an individual barcode 
(Fluidigm) using Expand High Fidelity PCR System (Roche), following manufacturers 
protocol (Access Array System for Illumina Systems User Guide). DNA was denatured at 
98 °C for 1 minute followed by 15 cycles of denaturing at 98 °C for 15 seconds, annealing at 
60 °C for 30 seconds and extension at 72 °C for 1 minute. Products were incubated at 72 °C 
for 3 minutes before cooling to 4 °C. Barcoded PCR samples were pooled for each patient 
and analysed using 2100 Bioanalyzer (Agilent) to determine the average size of the PCR 
library and by KAPA SYBR FAST qPCR (Anachem) to determine the library concentration. 
2 nM of each sample was analysed using MiSeq (Illumina).
The average sequencing depth across all mutations assessed within each patient varied 
between 4900 (in 8_T1) and 16600 (in 7_T4). However, for around a fifth of the targeted 
mutations within each patient, the average coverage across all samples from that patient was 
very much lower, 200 or lower. Many of these low coverage mutations had mutant allele 
frequencies very different from the values obtained from whole genome sequencing (WGS). 
These PCRs were considered to have failed and were not included in subsequent analysis.
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Due to the very high coverage, a low rate of sequencing errors was observed for most 
mutations. This manifested as a small percentage of aberrant reads, peaked close to zero and 
rapidly decaying exponentially with allele fraction. The rate of these errors was evaluated by 
considering those samples that reported no mutant reads in WGS. For this purpose, only 
mutations that were identified in samples that were previously identified as being 
phylogenetically related were included, in order to filter out low quality or questionable 
calls. Allele frequencies, fs, were converted to mutation copy numbers, nmut, as previously 
described39.
where ρ,  and  are, respectively, the tumor purity, the locus-specific copy number 
in the blood normal cells, inferred from the Battenberg algorithm. Mutation copy numbers 
correspond to the fraction of cells bearing a mutation multiplied by the number of 
chromosomal copies bearing the mutation and are more informative than raw allele 
frequencies as they are adjusted for tumour ploidy and normal cell contamination. The 
distribution of misreads was then found to have similar distributions for the different 
patients, with average reported mutation copy numbers of 0.0059 ± 0.0072, 0.0032 ± 0.0070 
and 0.0037 ± 0.0035 in patients 6, 7 and 8, respectively. The highest reported mutation copy 
number for these mutations was 0.041. This value was therefore used as a threshold for 
distinguishing between mutations present in a small proportion of cells and misreads arising 
from sequencing errors. It should be noted that a mutation copy number of 0.041 
corresponds to an allele frequency of ~1% for most mutations, since most mutations occur in 
diploid regions of the genome and the average tumour content across the samples is below 
50%.
For samples 6_T2, 6_T3 and 6_T4, it was apparent that nearly all mutations that were 
present in 6_T1 were identified at allele fractions slightly above the threshold used to 
exclude artefacts (corresponding to a mutation copy number ~0.05). Since these mutations 
were exclusively those present in 6_T1, it appears that ‘contamination’ of these 3 samples 
by 6_T1 occurred at some point during the PCR experiment, although whether this 
contamination is physical or the result of bleed-through of tags used in multiplexing is 
unknown. Assessment of WGS data, by checking the allele frequency of mutations 
identified uniquely in 6_T1 in samples 6_T2, 6_T3 and 6_T4, indicated that there may have 
been some intermixing of the cells 6_T1 with 6_T2, corresponding to a much lower 
percentage of cells (1.8%) and possibly arising from growth of cells in 6_T1 into the region 
sampled in 6_T2. Further, no evidence for intermixing of 6_T1 with 6_T3 or 6_T4 was 
found in WGS data. For this reason, mutations apparently present in the PCR experiment in 
6_T2, 6_T3 and 6_T4 and identified in 6_T1 in both WGS and PCR were only considered to 
be validated if they fell above a higher threshold, set to a mutation copy number of 0.2, that 
excluded mutant reads arising from the contamination of these samples.
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Mutational Signatures
The mutational spectra, as defined by the triplets of nucleotides around each mutation, of 
each sample was deconvoluted into mutational processes as described12,13.
Clustering of Mutations
We investigated regional clustering of substitution mutations by constructing plots (“rainfall 
plots”) in which the distance between each somatic substitution, and the substitution 
immediately before it has been plotted for each mutation. This was achieved exactly as 
described previously9.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Prostate samples chosen for whole-genome sequencing. a, ERG rearrangements determined 
by fluorescence in situ hybridization (FISH). Case 7 is a multifocal cancer containing two 
separate foci (T1/T2/T4/T5 and T3). Case 8 is also designated as a multifocal cancer,
(nodules T1/T2, and T3). Yellow: un-rearranged normal ERG gene; Red, ERG gene split but 
both 3′ and 5′ ends retained; Green, ERG gene rearranged but only its 3′ end retained. Panels 
b and c: 3-colour FISH used to distinguish different ERG-locus translocation breakpoints in 
Case 7. b, Position of the three FISH probes: probe 1 (blue, BAC RP11-164E1, and probe 
1a, BACs RP11-95G19, RP11-720N21, CTD-2511E13) was labeled in Aqua (Kreatech 415 
Platinum Bright): probe 2 (red, fosmid G248P80319F5 37Kb) labeled with Cy3; and Probe 
3 (green, fosmid G248P86592E2 38.5k, and probe 4, BACs RP11-372O17, RP11-115E14, 
RP11-729O4) labeled with FITC. The purple arrows represent the positions of ERG 
breakpoints detected in these experiments. For the precise position of the ERG breakpoints 
G and H see Table 2. c, Left: Tumor areas with ERG locus breaks G and H are indicated as 
light and dark green respectively. Break J was found in an adjacent prostate section not 
show in this figure. Right: representations of the ERG FISH patterns. Original FISH images 
are show in Supplementary Fig. 1. “Split” denotes that 5′ and 3′ ERG signals were separated 
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but retained in the cell. “Del” indicates that 5′ ERG signals were lost from the cell, while 3′ 
ERG signals were retained.
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Figure 2. 
Phylogenies of multi-focal prostate cancers. a-c, Phylogenies revealing the relationships 
between sample clones for each case. Each line is associated with a clone from a particular 
sample. The length of each line is proportional to the weighted quantity of variations on a 
logarithmic scale. The thickness of a line indicates the proportion the clone makes up of that 
sample i.e. 48%/52% for 6_T1 and 12%/88% for 8_T3. The minor clone of 8_T3b has no 
detected unique variants. 8_T3 contained 43 mutations present as a 12% subclone (T3a) 
shared with 8_T1/8_T2. In validation experiments 8_T3 did not contain any of the five ERG 
and TMPRSS2 rearrangements present in 8_T1/8_T2 (Table 2)) or mutations that were 
unique to 8_T1/8_T2 (10,000 depth) indicating that it represents an earlier clone of 
8_T1/8_T2 seeded into tissue sample 8_T3. The various TMPRSS2-ERG translocations are 
indicated by their TERG ID (Table 2). d, Example 2D density plots showing the posterior 
distribution of the fraction of cells bearing a mutation in two samples. The fraction of cells is 
modeled using a Bayesian Dirichlet processes. These plots illustrate samples that have 
shared clonal mutations (6_T1/6_T2), and branched (unrelated) mutations (7_T2/T_T3). 
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There are two examples of samples with a subclone. 7_T2/7_T5 has a peak at (0,0.72), 
which represents subclonal mutations in 72% of cells in 7_T5 that have occurred only in this 
sample, after divergence from the other samples. Similarly, 8_T1/8_T3 has a peak at 
(0.54,0), representing subclonal mutations in 54% of cells in T1 only.
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Figure 3. 
Patterns of ERG alterations. a-c, Circos plots highlighting ERG rearrangements present in 
each prostate. Each color represents a different cancer sample as indicated.
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Figure 4. 
Relative contributions of mutational signatures to the total mutation burden of each sample. 
The mutational spectra, as defined by the triplets of nucleotides around each substitution, of 
each sample were deconvoluted into mutational processes using 22 distinct signatures 
determined from 7,042 cancers as described previously12,13. The signature designations (1a, 
5, 8) match those reported previously12. For sample 7_T4 and 8_N there were too few 
mutations to be able to accurately identify the contributions of the mutational signatures.
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Table 1
Sample Description Gene Protein Description Type % reads Total num reads
MA 
predicted 
functional 
impact
ANNOVAR
significant
algorithms
0006#N chr9:g.131115799G>A SLC27A4 p.V435I misssense 13.79 58 low 1
0006#N chr14:g.20389481C>T OR4K5 p.T239M misssense 13.25 83 high 4
0006#N chr15:g.33873844G>T RYR3 p.A525S misssense 33.33 48 medium
0006#N chr4:g.88766379C>G MEPE p.S120* nonsense 20.83 24 2
0007#N chr5:g.150885254A>T FAT2 p.S4308T misssense 23.4 47 low 5
0007#N chr7:g.150934857G>T CHPF2 p.R470L misssense 17.24 58 medium 5
0007#N chr8:g.24192995G>A ADAM28 p.D470N misssense 17.78 45 neutral 2
0007#N chr12:g.24989522G>T BCAT1 p.L276M misssense 26.47 34 medium
Mutations and clonal expansions in morphologically normal tissue: point mutations present in exons with indication of functional significance. 
Missense and nonsense mutations detected and visually confirmed in the adjacent morphologically normal tissue were tested for functional impact 
using the MutationAssessor.org27 and wANNOVAR28 services. The OR4K5 gene was excluded as a candidate because of the potential to overcall 
mutations in genes encoding very large proteins29. Since none of the mutations had a high “MA” we considered that epigenetic changes may 
provide a more likely driver of clonal expansion.
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CS
 &
 P
 (8
_T
1);
 V
 (8
_T
1, 
8_
T2
)
8_
T1
, 8
_T
2
21
39
83
15
18
+
Ex
ac
t
-
-
-
21
42
87
04
97
−
in
ve
rs
io
n_
+
ER
G
-T
M
PR
SS
2
CS
 (8
_T
1);
 P 
& 
V 
(8_
T1
, 8
_T
2)
I
8_
T1
, 8
_T
2
21
42
84
44
60
−
H
O
M
O
LO
G
Y
T
21
42
85
16
48
+
in
ve
rs
io
n_
−
TM
PR
SS
2-
TM
PR
SS
2
V
 (8
_T
1, 
8_
T2
)
8_
T1
, 8
_T
2
21
42
86
37
87
−
H
O
M
O
LO
G
Y
G
21
42
87
06
63
+
in
ve
rs
io
n_
−
TM
PR
SS
2-
TM
PR
SS
2
CS
 &
 P
 (8
_T
1);
 V
 (8
_T
1, 
8_
T2
)
Pa
tte
rn
s o
f E
RG
 
al
te
ra
tio
ns
. P
os
iti
on
s a
nd
 st
ru
ct
ur
e 
of
 e
ac
h 
ER
G
 
br
ea
kp
oi
nt
s a
nd
 re
la
te
d 
re
ar
ra
ng
em
en
ts.
 T
he
 p
os
iti
on
 a
nd
 st
ru
ct
ur
e 
of
 th
e 
br
ea
kp
oi
nt
 w
as
 d
et
er
m
in
ed
, i
n 
th
e 
m
ajo
rity
 of
 ca
ses
, b
y c
ap
illa
ry 
se
qu
en
ci
ng
 u
sin
g 
cu
sto
m
-d
es
ig
ne
d 
PC
R 
ac
ro
ss
 th
e 
re
ar
ra
ng
em
en
t b
re
ak
po
in
t a
s p
re
vi
ou
sly
 d
es
cr
ib
ed
30
 
(“C
S”
 in
 co
lum
n “
Ve
rif
ica
tio
n”
), a
nd
/or
 by
 in
-s
ili
co
 
re
co
n
st
ru
ct
io
n 
us
in
g 
lo
ca
l d
e 
no
vo
 a
ss
em
bl
y 
in
 
B
ra
ss
 p
ha
se
 2
. V
er
ifi
ca
tio
n 
by
 si
zi
ng
 P
CR
 p
ro
du
ct
s a
cr
os
s t
he
 b
re
ak
po
in
t u
sin
g 
ge
l e
le
ct
ro
ph
or
es
is 
w
as
 a
lso
 p
er
fo
rm
ed
 (“
P”
). A
ll b
rea
kp
oin
ts 
we
re 
vis
ua
lly
 ve
rif
ied
 (“
V”
) t
o e
ns
ure
 th
e p
res
en
ce
 of
 
di
sc
or
da
nt
 re
ad
s a
nd
 c
he
ck
ed
 th
at
 th
ey
 d
id
 n
ot
 o
cc
ur
 in
 re
pe
at
 re
gi
on
s.
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